As nucleophosmin 1 gene mutations (NPM1mut) is a frequent marker, present in 30% of all AML patients and in 50% of those with normal karyotype, mutation-specific RQ-PCR assays have been developed for MRD monitoring [6-10]. This evidence concerns the gene NPM1 and acute myeloid leukemia.